When developed, these tracers may allow, (1) the identification of patients at prodromal or early stages of an α-synucleinopathy, (2) evaluation of the degree, location, and progression of the disease, as well as therapeutic effectiveness, (3) differentiation of α-synucleinopathies (LBSD and MSA) from tauopathies (PSP and CBD) and AD, and (4) insights into the contribution of α-synuclein pathology for clinical outcomes (320). This evidence concerns the gene SNCA and multiple system atrophy.